Loading company…
Ray Therapeutics develops optogenetic gene therapies for patients with degenerative retinal diseases.
Founded in 2021 and based in California, Ray Therapeutics develops gene therapies for blinding diseases, including retinitis pigmentosa and Stargardt disease. In April 2026, it raised USD 125 million in Series B funding led by Janus Henderson Investors, with Adage Capital Management, Franklin Templeton, Invus Financial Advisors, Marshall Wace, 4BIO Capital Partners, Deerfield Management, MRL Ventures Fund, Norwest Venture Partners, Novo Holdings, and Platanus Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in